Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
DUBLIN - Morgan Stanley Capital Services LLC disclosed its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) securities, according to a regulatory filing published Tuesday.
The disclosure, made under Rule 38.5(a) of the Irish Takeover Panel Act, revealed that Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, conducted several transactions in Avadel shares on December 1, 2025.
The filing showed that Morgan Stanley purchased 328 ordinary shares of Avadel at prices ranging from $21.4437 to $21.4567 per share, while selling 126 shares at prices between $21.4200 and $21.4316.
Additionally, the firm engaged in cash-settled derivative transactions involving Avadel shares, including increasing short positions by 251 reference securities and long positions by 3 reference securities, while reducing a short position by 45 reference securities.
Morgan Stanley Capital Services LLC is connected to Avadel Pharmaceuticals plc in relation to the disclosed transactions, according to the filing.
The disclosure was made in compliance with Irish takeover regulations that require principal traders to report dealings in securities of companies involved in takeover situations.
The information was submitted to the Irish Takeover Panel as part of standard regulatory requirements based on a press release statement from Morgan Stanley.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.